Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Rev Mol Diagn. 2007 Sep;7(5):635-46.

Biomarkers for Alzheimer's disease.

Author information

  • 1Proteome Sciences plc, South Wing Laboratory (PO 045), Institute of Psychiatry, London, SE5 8AF, UK. malcolm.ward@proteomics.com

Abstract

Alzheimer's disease (AD) is a horribly debilitating disease that will increase in prevalence as the populations of the USA and Europe continue to age. It is expected that the USA alone will see some 16 million cases by 2050. At present, there is no cure for the disease and early diagnosis is all but impossible. The onset of disease is not manifested clinically and little is known regarding the cause of nonfamiliar AD. There is a need for biomarkers associated with AD to aid the diagnosis of this disease and to detect progression. Especially needed are biomarkers to monitor the effect of new drugs and therapeutic strategies as they are developed. A biomarker may be a genetic trait, a biochemical change, such as a protein, peptide or metabolite, or a change in a structural or functional feature detected using imaging technology. This review aims to cover the important field of biomarker research in association with AD.

PMID:
17892369
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk